Co-Diagnostics Q2 2024 GAAP EPS $(0.25) Beats $(0.34) Estimate, Sales $2.656M Beat $375.000K Estimate
Portfolio Pulse from Benzinga Newsdesk
Co-Diagnostics (NASDAQ:CODX) reported Q2 2024 GAAP EPS of $(0.25), beating the $(0.34) estimate. Sales were $2.656M, significantly surpassing the $375K estimate and showing a 1.24K% increase from the same period last year.
August 08, 2024 | 8:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Co-Diagnostics reported better-than-expected Q2 2024 results with EPS of $(0.25) beating estimates by 26.47% and sales of $2.656M surpassing estimates by 608.27%. This represents a significant 1.24K% increase in sales YoY.
The better-than-expected earnings and significant sales growth are likely to positively impact CODX's stock price in the short term. Beating both EPS and sales estimates by a wide margin indicates strong performance and potential investor confidence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100